miRagen Therapeutics completes merger with Signal Genetics, raises $40.7M in equity financing
BOULDER -- Miragen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, announced its merger with... Read More
Monday February 20, 2017
MiRagen Therapeutics, Signal Genetics sign merger agreement
BOULDER --Miragen Therapeutics and California-based Signal Genetics, Inc. (Nasdaq: SGNL) today announced they have entered into a definitive merger agreement in which the stockholders of miRagen... Read More
Tuesday November 1, 2016
miRagen Therapeutics named to FierceBiotech's Fierce 15 List of most promising biotech firms
BOULDER - FierceBiotech has named miRagen Therapeutics one of 2012's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. "Over the past... Read More
Thursday September 20, 2012
IN Sponsors
Browse
Entrepreneurial by Nature
